Non-alcoholic fatty liver disease (NAFLD), as one of the main causes of chronic liver disease
worldwide, encompasses a spectrum of liver conditions that are not caused by other …

Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)-α/γ agonist,
has been used to treat metabolic diseases such as insulin resistance and diabetic …

Background Excess body weight has been found to associate with an increased risk of
lymphomas and some metabolic pathways are currently recognized in lymphomagenesis …

Diet-induced obesity mouse models are widely utilized to investigate the underlying
mechanisms of dyslipidemia, glucose intolerance, insulin resistance, hepatic steatosis, and …

Nonalcoholic fatty liver disease (NAFLD) is a prevalent global condition and a common
precursor to liver cancer, yet there is currently no specific medication available for its …

Objective To undertake a network meta-analysis to compare the relative efficacy of a dual
peroxisome proliferator-activated receptor (PPAR) α and PPARγ agonist, glucagon-like …

We evaluated the effects of select herbal extracts (Tinospora cordifolia [TC], Tinospora
cordifolia with Piper longum [TC+ PL], Withania somnifera [WS], Glycyrrhiza glabra [GG] …

The methionine-choline-deficient (MCD) diet-induced non-alcoholic steatohepatitis (NASH)
in mice is a well-established model. Our study aims to elucidate the factors influencing liver …

Diet-based models are commonly used to investigate obesity and related disorders. We
conducted a comparative profiling of three obesogenic diets HFD, high fat diet; HFHF, high …

Ethnopharmacological relevance Hepatic steatosis, a hallmark of non-alcoholic fatty liver
disease (NAFLD), represents a significant global health issue. Liver lipidomics has garnered …